Literature DB >> 28609557

Validation of international consensus equation for acute serum total tryptase in mast cell activation: A perioperative perspective.

R L Baretto1,2,3, S Beck1, J Heslegrave1, C Melchior1, O Mohamed1, A Ekbote1, A P Huissoon1,4, M T Krishna1,4.   

Abstract

There is no standardized method for assessing serum total mast cell tryptase (MCT) in anaphylaxis. The consensus equation (peak MCT should be>1.2× baseline tryptase+2 mg/L) has been proposed to interpret acute MCT in mast cell activation syndrome (MCAS). To validate consensus equation in a perioperative setting analyses of cases of suspected perioperative anaphylaxis during general anaesthesia (GA) were performed. Anaphylaxis was defined as per World Allergy Organisation (WAO) criteria. Timed serial MCT measurements were mapped against the consensus equation and receiver operating characteristic (ROC) curves produced. A total of 82 patients (60 females, mean age 56.5 years±SD17.2) underwent investigation. Sixty (73%) patients fulfilled WAO criteria for anaphylaxis, and 22 patients did not. Aetiology included 59% IgE-mediated anaphylaxis, 2% non-IgE-mediated anaphylaxis, 12% anaphylaxis of unknown cause and 27% deemed non-anaphylaxis. IgE-mediated anaphylaxis included the following: NMBA (35%), antibiotics (46%), chlorhexidine (8%), patent blue dye (8%) and others (8%). An acute MCT with a comparable baseline was available in 71 of 82 (87%) patients (60 anaphylaxis and 11 controls). The median interquartile range (IQR) time from reaction to peak MCT was 1.34 (0.82-2.51) hours. Analyses confirmed that a rise in acute MCT greater than that defined by the equation had a sensitivity, specificity, positive predictive value (PPV) and negative (N) PV of 78%, 91%, 98% and 44%, respectively. The magnitude of increase in acute MCT above the threshold predicted by consensus equation was higher in the anaphylaxis group compared to controls (P=.0001). This equation has a high specificity, PPV with a moderate NPV and sensitivity in perioperative anaphylaxis.
© 2017 EAACI and John Wiley and Sons A/S. Published by John Wiley and Sons Ltd.

Entities:  

Keywords:  anaphylaxis; drug allergy; mast cells; tryptase

Mesh:

Substances:

Year:  2017        PMID: 28609557     DOI: 10.1111/all.13226

Source DB:  PubMed          Journal:  Allergy        ISSN: 0105-4538            Impact factor:   13.146


  14 in total

Review 1.  Proposed Diagnostic Algorithm for Patients with Suspected Mast Cell Activation Syndrome.

Authors:  Peter Valent; Cem Akin; Patrizia Bonadonna; Karin Hartmann; Knut Brockow; Marek Niedoszytko; Boguslaw Nedoszytko; Frank Siebenhaar; Wolfgang R Sperr; Joanna N G Oude Elberink; Joseph H Butterfield; Ivan Alvarez-Twose; Karl Sotlar; Andreas Reiter; Hanneke C Kluin-Nelemans; Olivier Hermine; Jason Gotlib; Sigurd Broesby-Olsen; Alberto Orfao; Hans-Peter Horny; Massimo Triggiani; Michel Arock; Lawrence B Schwartz; Dean D Metcalfe
Journal:  J Allergy Clin Immunol Pract       Date:  2019-02-05

2.  Mast cell activation syndrome: Importance of consensus criteria and call for research.

Authors:  Peter Valent; Cem Akin; Patrizia Bonadonna; Karin Hartmann; Sigurd Broesby-Olsen; Knut Brockow; Joseph H Butterfield; Andreas Reiter; Jason Gotlib; Mariana Castells; Joshua D Milner; Melody C Carter; Hirsh Komarow; Deepti Radia; Animesh Pardanani; Karl Sotlar; Massimo Triggiani; Hans-Peter Horny; Michel Arock; Lawrence B Schwartz; Dean D Metcalfe
Journal:  J Allergy Clin Immunol       Date:  2018-06-19       Impact factor: 10.793

Review 3.  Why the 20% + 2 Tryptase Formula Is a Diagnostic Gold Standard for Severe Systemic Mast Cell Activation and Mast Cell Activation Syndrome.

Authors:  Peter Valent; Patrizia Bonadonna; Karin Hartmann; Sigurd Broesby-Olsen; Knut Brockow; Joseph H Butterfield; Massimo Triggiani; Jonathan J Lyons; Joanna N G Oude Elberink; Michel Arock; Dean D Metcalfe; Cem Akin
Journal:  Int Arch Allergy Immunol       Date:  2019-06-28       Impact factor: 2.749

4.  Defining baseline variability of serum tryptase levels improves accuracy in identifying anaphylaxis.

Authors:  Allyson Mateja; Qinlu Wang; Jack Chovanec; Jiwon Kim; Kenneth J Wilson; Lawrence B Schwartz; Sarah C Glover; Melody C Carter; Dean D Metcalfe; Erica Brittain; Jonathan J Lyons
Journal:  J Allergy Clin Immunol       Date:  2021-08-20       Impact factor: 14.290

Review 5.  Biomarkers in Human Anaphylaxis: A Critical Appraisal of Current Evidence and Perspectives.

Authors:  Sarah C Beck; Thomas Wilding; Richard J Buka; Richard L Baretto; Aarnoud P Huissoon; Mamidipudi T Krishna
Journal:  Front Immunol       Date:  2019-04-05       Impact factor: 7.561

6.  Editorial: Anaphylaxis - A Distinct Immunological Syndrome, but How Much Do We Really Understand?

Authors:  Mamidipudi Thirumala Krishna; Margitta Worm; Maria Beatrice Bilo
Journal:  Front Immunol       Date:  2019-12-19       Impact factor: 7.561

Review 7.  Diagnosis, Classification and Management of Mast Cell Activation Syndromes (MCAS) in the Era of Personalized Medicine.

Authors:  Peter Valent; Cem Akin; Boguslaw Nedoszytko; Patrizia Bonadonna; Karin Hartmann; Marek Niedoszytko; Knut Brockow; Frank Siebenhaar; Massimo Triggiani; Michel Arock; Jan Romantowski; Aleksandra Górska; Lawrence B Schwartz; Dean D Metcalfe
Journal:  Int J Mol Sci       Date:  2020-11-27       Impact factor: 5.923

Review 8.  The 2020 update on anaphylaxis in paediatric population.

Authors:  Izabela Tarczoń; Ewa Cichocka-Jarosz; Anna Knapp; Przemko Kwinta
Journal:  Postepy Dermatol Alergol       Date:  2021-02-06       Impact factor: 1.837

9.  A Clinical Practice Guideline for the Emergency Management of Anaphylaxis (2020).

Authors:  Xiaotong Li; Qingbian Ma; Jia Yin; Ya'an Zheng; Rongchang Chen; Yuguo Chen; Tianzuo Li; Yuqin Wang; Kehu Yang; Hongjun Zhang; Yida Tang; Yaolong Chen; Hailong Dong; Qinglong Gu; Daihong Guo; Xuehui Hu; Lixin Xie; Baohua Li; Yuzhen Li; Tongyu Lin; Fang Liu; Zhiqiang Liu; Lanting Lyu; Quanxi Mei; Jie Shao; Huawen Xin; Fan Yang; Hui Yang; Wanhua Yang; Xu Yao; Chunshui Yu; Siyan Zhan; Guoqiang Zhang; Minggui Wang; Zhu Zhu; Baoguo Zhou; Jianqing Gu; Mo Xian; Yuan Lyu; Zhengqian Li; Hangci Zheng; Chang Cui; Shuhua Deng; Chao Huang; Lisha Li; Pengfei Liu; Peng Men; Chunli Shao; Sai Wang; Xiang Ma; Qiang Wang; Suodi Zhai
Journal:  Front Pharmacol       Date:  2022-03-28       Impact factor: 5.810

Review 10.  Estimating the within-subject (CVI ) and between-subject (CVG ) biological variation of serum tryptase.

Authors:  Birthe R Skarbø; Erik W Vinnes; Tore Wentzel-Larsen; Marit S Sylte; Torunn O Apelseth
Journal:  Immun Inflamm Dis       Date:  2021-12-13
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.